Should I buy or sell Alpine Immune Sciences stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares. View ALPN analyst ratings or view top-rated stocks .

What is Alpine Immune Sciences' stock price target for 2024?

11 brokers have issued 12 month target prices for Alpine Immune Sciences' stock. Their ALPN share price targets range from $18.00 to $65.00. On average, they predict the company's share price to reach $50.33 in the next year. This suggests that the stock has a possible downside of 21.9%. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts .

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 at the start of the year. Since then, ALPN shares have increased by 238.0% and is now trading at $64.43. View the best growth stocks for 2024 here .

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 5,280,000 shares, a decline of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is presently 4.4 days. View Alpine Immune Sciences' Short Interest .

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALPN earnings forecast .

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings results on Monday, March, 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.47. The biotechnology company had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%.

What ETFs hold Alpine Immune Sciences' stock?

ETFs with the largest weight of Alpine Immune Sciences (NASDAQ:ALPN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) , ALPS Medical Breakthroughs ETF (SBIO) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and Invesco Nasdaq Future Gen 200 ETF (QQQS) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Abeona Therapeutics (ABEO) , CymaBay Therapeutics (CBAY) , Genocea Biosciences (GNCA) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Energy Transfer (ET) and Palatin Technologies (PTN) .

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Banque Cantonale Vaudoise (0.03%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold , Orbimed Advisors Llc, Peter A Thompson and Robert E Conway . View institutional ownership trends .

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ALPN Stock Alerts

$64.43

-0.03 (-0.05%)

(As of 04/18/2024 ET)

Compare

Today's Range: $64.42
▼
$64.48
50-Day Range: $28.77
▼
$64.50
52-Week Range: $6.71
▼
$64.57

Volume: 2.46 million shs
Average Volume: 3.81 million shs
Market Capitalization: $4.22 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.33

Get Alpine Immune Sciences alerts:

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.27 Rating Score
Upside/Downside: 21.9% Downside
$50.33 Price Target
Short Interest: Healthy
8.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.68
Based on 33 Articles This Week
Insider Trading: Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.74) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

688th out of 918 stocks

Pharmaceutical Preparations Industry

299th out of 402 stocks

2.1

Analyst's Opinion

Consensus Rating
Alpine Immune Sciences has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Alpine Immune Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
8.06% of the outstanding shares of Alpine Immune Sciences have been sold short.
Short Interest Ratio / Days to Cover
Alpine Immune Sciences has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Alpine Immune Sciences has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alpine Immune Sciences does not currently pay a dividend.
Dividend Growth
Alpine Immune Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALPN.

3.2

News and Social Media Coverage

News Sentiment
Alpine Immune Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 33 news articles for Alpine Immune Sciences this week, compared to 3 articles on an average week.
Search Interest
41 people have searched for ALPN on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,192.00 in company stock.
Percentage Held by Insiders
42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.74) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alpine Immune Sciences is -100.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alpine Immune Sciences is -100.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alpine Immune Sciences has a P/B Ratio of 11.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALPN Stock News Headlines

April 18, 2024 | msn.com

TD Cowen Downgrades Alpine Immune Sciences (ALPN)

April 17, 2024 | prnewswire.com

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | msn.com

Alpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24

April 17, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD Cowen

April 17, 2024 | americanbankingnews.com

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

April 15, 2024 | investorplace.com

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

April 15, 2024 | americanbankingnews.com

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) to Post Q1 2024 Earnings of ($0.45) Per Share, Wedbush Forecasts

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 14, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume

April 14, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Cut to "Market Perform" at Leerink Partnrs

April 14, 2024 | americanbankingnews.com

SVB Leerink Downgrades Alpine Immune Sciences (NASDAQ:ALPN) to Market Perform